A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer

Papers of special note have been highlighted as:

• of interest

References

• 1 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11–30 (2013).
  MedlineGoogle Scholar
• 2 Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61(4), 212–236 (2011).
  MedlineGoogle Scholar
• 3 Grimm P, Billiet I, Bostwick D et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 109(Suppl. 1), 22–29 (2012).
  MedlineGoogle Scholar
• 4 Khan MA, Han M, Partin AW, Epstein JI, Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 62(1), 86–91; discussion: 91–82 (2003).
  MedlineGoogle Scholar
• 5 Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur. Urol. 43(1), 12–27 (2003).
  MedlineGoogle Scholar
• 6 Zaorsky NG, Raj GV, Trabulsi EJ, Lin J, Den RB. The dilemma of a rising PSA after local therapy: what are our options? Semin. Oncol. 40(3), 322–336 (2013).
  MedlineGoogle Scholar
• 7 King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int. J. Radiat. Oncol. Biol. Phys. 84(1), 104–111 (2012).
  MedlineGoogle Scholar
• 8 Scattoni V, Montorsi F, Picchio M et al. Diagnosis of local recurrence after radical prostatectomy. BJU Int. 93(5), 680–688 (2004).
  Medline CASGoogle Scholar
• 9 Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin. Oncol. (R. Coll. Radiol.) 22(1), 46–55 (2010). • Provides the recommendations for the current role of post-radical prostatectomy (RP) biochemical failure (BF) imaging for salvage external beam radiation therapy (EBRT).
  Medline CASGoogle Scholar
• 10 Rouviere O, Vitry T, Lyonnet D. Imaging of prostate cancer local recurrences: why and how? Eur. Radiol. 20(5), 1254–1266 (2010). • Reviews current recommendations for detection of local recurrence (LR) after treatment with various modalities.
  MedlineGoogle Scholar
• 11 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62(10), 1006–1012 (2009).
  MedlineGoogle Scholar
• 12 Coakley FV, Teh HS, Qayyum A et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233(2), 441–448 (2004).
  MedlineGoogle Scholar
• 13 Westphalen AC, Coakley FV, Roach M 3rd, Mcculloch CE, Kurhanewicz J. Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology 256(2), 485–492 (2010).
  MedlineGoogle Scholar
• 14 Sciarra A, Panebianco V, Salciccia S et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur. Urol. 54(3), 589–600 (2008).
  MedlineGoogle Scholar
• 15 Zakian KL, Sircar K, Hricak H et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234(3), 804–814 (2005).
  MedlineGoogle Scholar
• 16 Haider MA, Chung P, Sweet J et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70(2), 425–430 (2008).
  MedlineGoogle Scholar
• 17 Casciani E, Polettini E, Carmenini E et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am. J. Roentgenol. 190(5), 1187–1192 (2008).
  MedlineGoogle Scholar
• 18 Cirillo S, Petracchini M, Scotti L et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T₂-weighted and contrast-enhanced imaging. Eur. Radiol. 19(3), 761–769 (2009).
  MedlineGoogle Scholar
• 19 Panebianco V, Sciarra A, Lisi D et al. Prostate cancer: ¹HMRS-DCEMR at 3 T versus ¹⁸F-choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur. J. Radiol. 81(4), 700–708 (2012).
  MedlineGoogle Scholar
• 20 Kim CK, Park BK, Lee HM. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3 T diffusion-weighted MRI. J. Magn. Reson. Imaging 29(2), 391–397 (2009).
  MedlineGoogle Scholar
• 21 Giannarini G, Nguyen DP, Thalmann GN, Thoeny HC. Diffusion-weighted magnetic resonance imaging detects local recurrence after radical prostatectomy: initial experience. Eur. Urol. 61(3), 616–620 (2012).
  MedlineGoogle Scholar
• 22 Ross RW, Zietman AL, Xie W et al. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin. Imaging 33(4), 301–305 (2009).
  MedlineGoogle Scholar
• 23 Koontz BF, Mouraviev V, Johnson JL et al. Use of local ¹¹¹In-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 71(2), 358–361 (2008).
  Medline CASGoogle Scholar
• 24 Raj GV, Partin AW, Polascik TJ. Clinical utility of ¹¹¹indium-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 94(4), 987–996 (2002).
  MedlineGoogle Scholar
• 25 Wilkinson S, Chodak G. The role of ¹¹¹indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J. Urol. 172(1), 133–136 (2004).
  MedlineGoogle Scholar
• 26 Hinkle GH, Burgers JK, Neal CE et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using ¹¹¹indium capromab pendetide. Cancer 83(4), 739–747 (1998).
  Medline CASGoogle Scholar
• 27 Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 37(4), 261–269 (1998).
  Medline CASGoogle Scholar
• 28 Ramirez De Molina A, Rodriguez-Gonzalez A, Gutierrez R et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem. Biophys. Res. Commun. 296(3), 580–583 (2002).
  MedlineGoogle Scholar
• 29 Bander NH, Trabulsi EJ, Kostakoglu L et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol. 170(5), 1717–1721 (2003).
  Medline CASGoogle Scholar
• 30 Pandit-Taskar N, O’Donoghue JA, Morris MJ et al. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J. Nucl. Med. 49(7), 1066–1074 (2008).
  MedlineGoogle Scholar
• 31 Seltzer MA, Barbaric Z, Belldegrun A et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J. Urol. 162(4), 1322–1328 (1999).
  Medline CASGoogle Scholar
• 32 Chang CH, Wu HC, Tsai JJ, Shen YY, Changlai SP, Kao A. Detecting metastatic pelvic lymph nodes by ¹⁸F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol. Int. 70(4), 311–315 (2003).
  MedlineGoogle Scholar
• 33 Nunez R, Macapinlac HA, Yeung HW et al. Combined ¹⁸F-FDG and ¹¹C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J. Nucl. Med. 43(1), 46–55 (2002).
  MedlineGoogle Scholar
• 34 Schoder H, Herrmann K, Gonen M et al. 2-[¹⁸F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin. Cancer Res. 11(13), 4761–4769 (2005).
  MedlineGoogle Scholar
• 35 Vees H, Buchegger F, Albrecht S et al. ¹⁸F-choline and/or ¹¹C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/ml) after radical prostatectomy. BJU Int. 99(6), 1415–1420 (2007).
  Medline CASGoogle Scholar
• 36 Picchio M, Briganti A, Fanti S et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur. Urol. 59(1), 51–60 (2011).
  MedlineGoogle Scholar
• 37 Scattoni V, Picchio M, Suardi N et al. Detection of lymph-node metastases with integrated [¹¹C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur. Urol. 52(2), 423–429 (2007).
  MedlineGoogle Scholar
• 38 Giovacchini G, Picchio M, Briganti A et al. [¹¹C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J. Urol. 184(3), 938–943 (2010).
  MedlineGoogle Scholar
• 39 Reske SN, Blumstein NM, Glatting G. [¹¹C] choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging 35(1), 9–17 (2008).
  MedlineGoogle Scholar
• 40 Castellucci P, Fuccio C, Nanni C et al. Influence of trigger PSA and PSA kinetics on ¹¹C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J. Nucl. Med. 50(9), 1394–1400 (2009).
  MedlineGoogle Scholar
• 41 De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. ¹¹C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur. Urol. 44(1), 32–38; discussion 38–39 (2003).
  MedlineGoogle Scholar
• 42 Rinnab L, Simon J, Hautmann RE et al. [¹¹C] choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J. Urol. 27(5), 619–625 (2009).
  Medline CASGoogle Scholar
• 43 Breeuwsma AJ, Pruim J, Van Den Bergh AC et al. Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using (11)-choline positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys. 77(1), 160–164 (2010).
  MedlineGoogle Scholar
• 44 Giovacchini G, Picchio M, Scattoni V et al. PSA doubling time for prediction of [¹¹C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging 37(6), 1106–1116 (2010).
  Medline CASGoogle Scholar
• 45 Giovacchini G, Picchio M, Coradeschi E et al. Predictive factors of [¹¹C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging 37(2), 301–309 (2010).
  MedlineGoogle Scholar
• 46 Castellucci P, Fuccio C, Rubello D et al. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur. J. Nucl. Med. Mol. Imaging 38(1), 55–63 (2011).
  MedlineGoogle Scholar
• 47 Langsteger W, Balogova S, Huchet V et al. Fluorocholine (¹⁸F) and sodium fluoride (¹⁸F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q. J. Nucl. Med. Mol. Imaging 55(4), 448–457 (2011).
  Medline CASGoogle Scholar
• 48 Heinisch M, Dirisamer A, Loidl W et al. Positron emission tomography/computed tomography with ¹⁸F-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol. Imaging Biol. 8(1), 43–48 (2006).
  MedlineGoogle Scholar
• 49 Cimitan M, Bortolus R, Morassut S et al. [¹⁸F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur. J. Nucl. Med. Mol. Imaging 33(12), 1387–1398 (2006).
  MedlineGoogle Scholar
• 50 Schmid DT, John H, Zweifel R et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 235(2), 623–628 (2005).
  MedlineGoogle Scholar
• 51 Husarik DB, Miralbell R, Dubs M et al. Evaluation of [¹⁸F]-choline PET/CT for staging and restaging of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 35(2), 253–263 (2008).
  MedlineGoogle Scholar
• 52 Pelosi E, Arena V, Skanjeti A et al. Role of whole-body ¹⁸F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. La Radiologia Medica 113(6), 895–904 (2008).
  Medline CASGoogle Scholar
• 53 Oyama N, Miller TR, Dehdashti F et al. ¹¹C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J. Nucl. Med. 44(4), 549–555 (2003).
  Medline CASGoogle Scholar
• 54 Fricke E, Machtens S, Hofmann M et al. Positron emission tomography with ¹¹C-acetate and ¹⁸F-FDG in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 30(4), 607–611 (2003).
  Medline CASGoogle Scholar
• 55 Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 29(10), 1380–1384 (2002).
  Medline CASGoogle Scholar
• 56 Wachter S, Tomek S, Kurtaran A et al. ¹¹C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J. Clin. Oncol. 24(16), 2513–2519 (2006).
  MedlineGoogle Scholar
• 57 Beheshti M, Vali R, Waldenberger P et al. Detection of bone metastases in patients with prostate cancer by ¹⁸F fluorocholine and ¹⁸F fluoride PET-CT: a comparative study. Eur. J. Nucl. Med. Mol. Imaging 35(10), 1766–1774 (2008).
  MedlineGoogle Scholar
• 58 Futterer JJ. Imaging of recurrent prostate cancer. Radiol. Clin. North Am. 50(6), 1075–1083 (2012). • Provides a concise review of the role of MRI in the detection of recurrent prostate cancer.
  MedlineGoogle Scholar
• 59 Martino P, Scattoni V, Galosi AB et al. Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J. Urol. 29(5), 595–605 (2011).
  MedlineGoogle Scholar
• 60 Mohler JL, Armstrong A, Bahnson RR et al. NCCN Guideline: prostate cancer. Version 2.2013. www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
  Google Scholar
• 61 Dotan ZA, Bianco FJ Jr, Rabbani F et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J. Clin. Oncol. 23(9), 1962–1968 (2005).
  MedlineGoogle Scholar
• 62 Tamsel S, Killi R, Apaydin E, Hekimgil M, Demirpolat G. The potential value of power Doppler ultrasound imaging compared with grey-scale ultrasound findings in the diagnosis of local recurrence after radical prostatectomy. Clin. Radiol. 61(4), 325–330; discussion 323–324 (2006).
  Medline CASGoogle Scholar
• 63 Drudi FM, Giovagnorio F, Carbone A et al. Transrectal colour Doppler contrast sonography in the diagnosis of local recurrence after radical prostatectomy – comparison with MRI. Ultraschall Med. 27(2), 146–151 (2006).
  Medline CASGoogle Scholar
• 64 Kane CJ, Amling CL, Johnstone PA et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61(3), 607–611 (2003).
  MedlineGoogle Scholar
• 65 Sugimura K, Carrington BM, Quivey JM, Hricak H. Postirradiation changes in the pelvis: assessment with MR imaging. Radiology 175(3), 805–813 (1990).
  Medline CASGoogle Scholar
• 66 Miralbell R, Vees H, Lozano J et al. Endorectal MRI assessment of local relapse after surgery for prostate cancer: a model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int. J. Radiat. Oncol. Biol. Phys. 67(2), 356–361 (2007).
  MedlineGoogle Scholar
• 67 Sella T, Schwartz LH, Swindle PW et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231(2), 379–385 (2004).
  MedlineGoogle Scholar
• 68 Okotie OT, Aronson WJ, Wieder JA et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J. Urol. 171(6 Pt 1), 2260–2264 (2004).
  MedlineGoogle Scholar
• 69 Gomez P, Manoharan M, Kim SS, Soloway MS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int. 94(3), 299–302 (2004).
  MedlineGoogle Scholar
• 70 Cher ML, Bianco FJ, Jr., Lam JS et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J. Urol. 160(4), 1387–1391 (1998).
  Medline CASGoogle Scholar
• 71 Picchio M, Giovannini E, Crivellaro C, Gianolli L, Di Muzio N, Messa C. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiother. Oncol. 96(3), 347–350 (2010). • Provides an overview of PET/computed tomography in radiation planning, with a particular focus on 11C-choline.
  MedlineGoogle Scholar
• 72 Scattoni V, Roscigno M, Raber M et al. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur. Urol. 44(4), 407–414 (2003).
  MedlineGoogle Scholar
• 73 Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 219(2), 432–439 (2001).
  Medline CASGoogle Scholar
• 74 Deliveliotis C, Manousakas T, Chrisofos M, Skolarikos A, Delis A, Dimopoulos C. Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy. World J. Urol. 25(3), 309–313 (2007).
  MedlineGoogle Scholar
• 75 Crook J, Robertson S, Collin G, Zaleski V, Esche B. Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 27(1), 31–37 (1993).
  Medline CASGoogle Scholar
• 76 Pucar D, Sella T, Schoder H. The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr. Opin. Urol. 18(1), 87–97 (2008).
  MedlineGoogle Scholar
• 77 Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int. J. Radiat. Oncol. Biol. Phys. 48(2), 355–367 (2000).
  Medline CASGoogle Scholar
• 78 Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen Li. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int. J. Radiat. Oncol. Biol. Phys. 54(3), 677–685 (2002).
  MedlineGoogle Scholar
• 79 Ahmed HU, Kirkham A, Arya M et al. Is it time to consider a role for MRI before prostate biopsy? Nat. Rev. Clin. Oncol. 6(4), 197–206 (2009).
  MedlineGoogle Scholar
• 80 Turkbey B, Choyke PL. Multiparametric MRI and prostate cancer diagnosis and risk stratification. Curr. Opin. Urol. 22(4), 310–315 (2012).
  MedlineGoogle Scholar
• 81 Augustin H, Fritz GA, Ehammer T, Auprich M, Pummer K. Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables. Acta Radiol. 50(5), 562–569 (2009).
  Medline CASGoogle Scholar
• 82 Seitz M, Shukla-Dave A, Bjartell A et al. Functional magnetic resonance imaging in prostate cancer. Eur. Urol. 55(4), 801–814 (2009).
  Medline CASGoogle Scholar
• 83 Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 59(1), 61–71 (2011).
  MedlineGoogle Scholar
• 84 Thompson IM, Valicenti R, Albertsen PC et al. Adjuvant and salvage radiotherapy after prostatectomy: ASTRO/AUA guideline. www.auanet.org/education/guidelines/radiation-after-prostatectomy.cfm
  Google Scholar
• 85 Hom JJ, Coakley FV, Simko JP et al. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging–distinction of true-positive results from chance-detected lesions. Radiology 238(1), 192–199 (2006).
  MedlineGoogle Scholar
• 86 Rouviere O, Valette O, Grivolat S et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor–correlation with biopsy findings. Urology 63(5), 922–927 (2004).
  MedlineGoogle Scholar
• 87 Ocak I, Bernardo M, Metzger G et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Am. J. Roentgenol. 189(4), W192–W201 (2007).
  Google Scholar
• 88 Harisinghani MG, Barentsz J, Hahn PF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348(25), 2491–2499 (2003).
  MedlineGoogle Scholar
• 89 Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 12(2), 181–191 (2011). • Provides an overview of current and future targets in radionuclide imaging and hybrid imaging for assessment of recurrent prostate cancer.
  MedlineGoogle Scholar
• 90 Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P. PET/CT imaging and radioimmunotherapy of prostate cancer. Semin. Nucl. Med. 41(1), 29–44 (2011). • Reviews the current status and future directions of PET/CT and radioimmunoscintigraphy in prostate cancer.
  MedlineGoogle Scholar
• 91 Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin. Nucl. Med. 23(10), 672–677 (1998).
  Medline CASGoogle Scholar
• 92 Deb N, Goris M, Trisler K et al. Treatment of hormone-refractory prostate cancer with ⁹⁰Y-CYT-356 monoclonal antibody. Clin. Cancer Res. 2(8), 1289–1297 (1996).
  Medline CASGoogle Scholar
• 93 Wynant GE, Murphy GP, Horoszewicz JS et al. Immunoscintigraphy of prostatic cancer: preliminary results with ¹¹¹In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 18(3), 229–241 (1991).
  Medline CASGoogle Scholar
• 94 Nagda SN, Mohideen N, Lo SS et al. Long-term follow-up of ¹¹¹In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 67(3), 834–840 (2007).
  Medline CASGoogle Scholar
• 95 Machtens S, Serth J, Meyer A et al. Positron emission tomography (PET) in the urooncological evaluation of the small pelvis. World J. Urol. 25(4), 341–349 (2007).
  Medline CASGoogle Scholar
• 96 Farsad M, Schiavina R, Castellucci P et al. Detection and localization of prostate cancer: correlation of ¹¹C-choline PET/CT with histopathologic step-section analysis. J. Nucl. Med. 46(10), 1642–1649 (2005).
  Medline CASGoogle Scholar
• 97 Reske SN, Blumstein NM, Neumaier B et al. Imaging prostate cancer with ¹¹C-choline PET/CT. J. Nucl. Med. 47(8), 1249–1254 (2006).
  Medline CASGoogle Scholar
• 98 Giovacchini G, Picchio M, Coradeschi E et al. [¹¹C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur. J. Nucl. Med. Mol. Imaging 35(6), 1065–1073 (2008).
  Medline CASGoogle Scholar
• 99 Schilling D, Schlemmer HP, Wagner PH et al. Histological verification of ¹¹C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int. 102(4), 446–451 (2008).
  MedlineGoogle Scholar
• 100 Van Poppel H. Is radiotherapy useful in node-positive prostate cancer patients after radical prostatectomy? Eur. Urol. 55(5), 1012–1013 (2009).
  MedlineGoogle Scholar
• 101 Jadvar H. Prostate cancer: PET with ¹⁸F-FDG, ¹⁸F- or ¹¹C-acetate, and ¹⁸F- or ¹¹C-choline. J. Nucl. Med. 52(1), 81–89 (2011).
  MedlineGoogle Scholar
• 102 Albrecht S, Buchegger F, Soloviev D et al. ¹¹C-acetate PET in the early evaluation of prostate cancer recurrence. Eur. J. Nucl. Med. Mol. Imaging 34(2), 185–196 (2007).
  MedlineGoogle Scholar
• 103 Swinnen JV, Van Veldhoven PP, Timmermans L et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem. Biophys. Res. Commun. 302(4), 898–903 (2003).
  Medline CASGoogle Scholar
• 104 Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: ^99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, ¹⁸F-fluoride PET, and ¹⁸F-fluoride PET/CT. J. Nucl. Med. 47(2), 287–297 (2006).
  MedlineGoogle Scholar
• 105 Jadvar H, Desai B, Ji L et al. Prospective evaluation of ¹⁸F-NaF and ¹⁸F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin. Nucl. Med. 37(7), 637–643 (2012).
  MedlineGoogle Scholar
• 106 Even-Sapir E, Metser U, Flusser G et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between ¹⁸F-fluoride PET and ¹⁸F-fluoride PET/CT. J. Nucl. Med. 45(2), 272–278 (2004).
  MedlineGoogle Scholar
• 107 Beattie BJ, Smith-Jones PM, Jhanwar YS et al. Pharmacokinetic assessment of the uptake of 16beta-¹⁸F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J. Nucl. Med. 51(2), 183–192 (2010).
  Medline CASGoogle Scholar
• 108 Dehdashti F, Picus J, Michalski JM et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur. J. Nucl. Med. Mol. Imaging 32(3), 344–350 (2005).
  MedlineGoogle Scholar
• 109 Hong H, Zhang Y, Sun J, Cai W. Positron emission tomography imaging of prostate cancer. Amino Acids 39(1), 11–27 (2010).
  Medline CASGoogle Scholar
• 110 Clinical trials database. http://clinicaltrials.gov
  Google Scholar
• 111 A Phase 2 diagnostic imaging study with ^99mTc-MIP-1404 in men with high-risk prostate cancer scheduled for radical prostatectomy (RP) and extended pelvic lymph node dissection (EPLND) compared to histopathology. http://clinicaltrials.gov/show/NCT01667536
  Google Scholar
• 112 Hurwitz MD, Zaorsky NG. Image-guided focused ultrasound for the treatment of bone metastases: current status and future direction. Curr. Radiol. Rep. 10(3), 1–7 (2013).
  Google Scholar
• 113 Vogelzang N, Parker C, Nilsson S et al. Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the Phase III randomized trial (ALSYMPCA). J. Clin. Oncol. 31(Suppl. 6), Abstract 11 (2013).
  MedlineGoogle Scholar